Impact of recent black box warnings in the allergy world

Annals of Allergy, Asthma and Immunology

Volumn 99, Issue 4, 2007, Pages 364-366

  Oppenheimer, John ^a,b   Aaronson, Donald ^c  

^a Pulmonary and Allergy Associates PA   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; PIMECROLIMUS; TACROLIMUS;

ALLERGY; ASTHMA; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG LABELING; DRUG MISUSE; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMED CONSENT; MONOTHERAPY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY; TREATMENT RESPONSE;

EID: 35348995924     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60554-6     Document Type: Article

References (17)

1. Physicians' Desk Reference. 61st ed. Montvale, NJ: Thomson PDR; 2007:1318.
2. Physicians' Desk Reference. 61st ed. Montvale, NJ: Thomson PDR; 2007:639.
3. Nelson HS, Weiss ST, Bleecker ER, et al; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26.
4. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368-1373.
5. 2- agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;285:2583-2593.
6. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034-1037.
7. Lemanske RF Jr, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 2001;285:2594-2603.
8. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med. 1998;158:924-930.
9. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, MD: Global Initiative for Asthma; 2006. http://www.ginasthma.com.
10. Wechsler ME, Lehman E, Lazarus SC, et al. β-adrenergic receptor polymorphism and response to salmeterol. Am J Respir Crit Care Med. 2006;173:519-526.
11. Papp KA, Werfel T, Folster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol. 2005;52:240-246.
12. Reitamo S, Wollenberg A, Schopf E, et al; European Tacrolimus Ointment Study Group. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol. 2000;136:999-1006.
13. Pediatric Advisory Committee Meeting of the US Food Drug Administration. Novartis Pharmaceutical Corp and Fujisawa Healthcare Inc FDA Briefing Statements. Washington, DC: Pediatric Advisory Committee Meeting, Food Drug Administration; 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005- 4089b2.htm. Accessed March 16, 2005.
14. Kapp MB. Patient autonomy in the age of consumer-driven health care: informed consent and informed choice. J Legal Med. 2007;28:91-117.
15. IMS Health National Prescription Audit. Norwalk, CT: IMS Health; January 2007.
16. Schloendorff v Society of New York Hospital, 211 NY125, 105 NE 92 (1914).
17. Bianco EA, Hirsh HL. Consent to and refusal of medical treatment. In: Gibofsky A, Firestone MH, LeBlang TR, eds. Legal Medicine, 3rd ed. St Louis: Mosby-Year Book; 1995:274-296.